Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   CRISPR

BioPharma« Terug naar discussie overzicht

CRISPR

Volgen
53 Posts
Pagina: «« 1 2 3 »» | Laatste | Omlaag ↓
  6. Stefaan_ 16 april 2018 11:43
    rispr sees gene therapy milestone in Europe
    Apr. 16, 2018 3:10 AM ET|By: Yoel Minkoff, SA News Editor

    Humans are set to be genetically modified for the first time in Europe after regulators gave the go ahead to trial Crispr Therapeutics' (NASDAQ:CRSP) DNA-splicing therapy.

    A destructive blood disorder known as beta thalassaemia could be cured by altering the body's code and restoring healthy levels of haemoglobin.

    "We will look back and think that this is the real beginning of gene therapy," said Prof. Robin Lovell-Badge of London's Francis Crick Institute.

    Now read: Time Out: Talking Strategy For CRISPR's Big 3 »
  8. MarkvB 7 januari 2021 20:24
    Imara declined yesterday as its sickle cell treatment appears to be not at par with its peers

    Jan. 07, 2021 7:36 AM ETIMARA Inc. (IMRA)By: Vandana Singh, SA News Editor
    Imara (NASDAQ:IMRA) closed in red, down 38% yesterday as investors apparently saw the company's sickle cell data lacked benefit when compared to its peers.
    Data showed that IMR-687 had no meaningful impact on key measures like fetal hemoglobin ((HbF)) or hemoglobin levels when taken by itself. Combination with HU showed slight benefits in F- cells and fetal hemoglobin levels but hemoglobin decreased on average after 24 weeks.
    Three of eight combination patients had absolute increases in HbF percentage of greater than 1%, with a mean absolute increase in HbF percentage of 4.3% in that subset of patients
    Global Blood Therapeutics and Novartis already have approved therapies to treat sickle cell patients while one-time treatments from Bluebird bio (NASDAQ:BLUE) and Vertex/Crispr (NASDAQ:VRTX) (NASDAQ:CRSP) have shown promise for potentially curative therapies, raising the bar.
    SVB Leerink analyst Joe Schwartz defended the company stating that Covid-19 hurt the trial because of missed visits that “potentially undermined the quality of the data”.
    He also cited that the drug doses examined are much lower than those expected in future trials, and he believes that “longer and higher dosing” could lead to improved efficacy.
    SVB Leerink said in a note "Imara’s Phase 2a data announced Wednesday represents a “rearward looking view of IMR-687’s development” and isn’t likely a good indicator of what’s to come in future readouts". Sees the stock’s weakness as a potential buying opportunity ahead of IMRA’s multiple data readouts in 2021.
    Imara shares are up 3% in premarket trading today.
  9. MarkvB 7 januari 2021 22:46
    CRISPR doubles lifespan of mice with rapid ageing disease progeria

    HEALTH 6 January 2021
    By Michael Le Page
    A cell from a person with progeria
    A cell from a person with progeria
    ALVIN TELSER/SCIENCE PHOTO LIBRARY

    CRISPR gene editing has been used to more than double the lifespan of mice engineered to have the premature ageing disease progeria, also greatly improving their health.
    The results far surpassed expectations. Progeria affects many different organs in the body, and the team behind the work didn’t expect that correcting the mutation in a relatively low proportion of cells – 10 to 60 per cent – would have such a big effect. “We were quite amazed,” says David Liu at Harvard University.
    Hutchinson-Gilford progeria syndrome is a rare condition caused when a mutation, which probably took place in the testes or ovaries of a child’s parents, results in a single DNA letter change in one of the two copies of the gene for the lamin A protein. This leads to the production of an abnormal protein called progerin that interferes with cell division and causes many symptoms of premature ageing. The average lifespan of children with progeria is 14 years.
    Advertisement
    Conventional gene therapy, which involves adding genes, cannot help. People with progeria still have one healthy copy of the lamin A gene – the problem is the mutant progerin protein.
    The standard form of CRISPR gene editing, which involves cutting DNA with the Cas9 protein, can be used to disable the mutant gene. The trouble is that it often disables the healthy copy too, as well as causing other unwanted changes.
    Liu’s team has been modifying the Cas9 protein so instead of cutting DNA, it changes one DNA letter to another, a process known as base editing. He and his colleagues have now used a CRISPR base editor to correct the single-letter change that causes almost all cases of progeria, first in skin cells taken from a person with progeria and then in mice with a human version of the lamin A gene.
    Read more: The powerhouses inside cells have been gene-edited for the first time
    A virus carrying the genes for the base editor was injected into the blood of 2-week-old mice – roughly equivalent to 5-year-old children, says Liu – with the progeria mutation. A single injection boosted the median lifespan from 215 to 510 days, and the treated mice were also far more active.
    Because the mice had the human gene, exactly the same approach could be used in human trials. However, Liu’s team has already developed even more efficient base editors.
    In November 2020, the US Food and Drug Administration approved the first-ever drug for treating progeria. In trials, it increased lifespan by an average of 2.5 years over the maximum follow-up time of 11 years. Liu thinks combining this drug with the CRISPR base editing will work well.
    The findings also boost hopes that many other conditions could be treated through base editing. Half of all known disease-causing mutations involve a single-letter change, most of which can be corrected with existing base editors, says Liu.

    Read more: www.newscientist.com/article/2264168-...
  10. [verwijderd] 16 januari 2021 11:07
    Goedemorgen,

    Sinds kort ben ik geïnteresseerd geraakt in Crispr en wellicht nog andere bedrijven die DNA kunnen aanpassen.
    Ik zie in deze (bio hacking) technologie wel toekomst, verder zal ik mij nog wat meer moeten inlezen in deze wereld.

    - Hoever zijn ze in het proces?
    - Zijn er licenties?
    - Wordt het gereguleerd?
    - Kosten?
    - En al het andere wat van belang is

    Ik kan mij voorstellen dat overheden niet happig zijn op deze technologie.
    Het kan volgens mij ziektes en of aandoeningen aanpakken via DNA hacking maar dit kan natuurlijk ook toegepast worden voor foute doeleinde, het perfectioneren van de mens, blauwe ogen, meer spiergroei en noem maar op.

    Of heb ik het fout?

    Groeten!
  14. [verwijderd] 18 juni 2021 08:41
    quote:

    MarkvB schreef op 7 januari 2021 22:46:

    CRISPR doubles lifespan of mice with rapid ageing disease progeria

    HEALTH 6 January 2021
    By Michael Le Page
    A cell from a person with progeria
    A cell from a person with progeria
    ALVIN TELSER/SCIENCE PHOTO LIBRARY

    CRISPR gene editing has been used to more than double the lifespan of mice engineered to have the premature ageing disease progeria, also greatly improving their health.
    The results far surpassed expectations. Progeria affects many different organs in the body, and the team behind the work didn’t expect that correcting the mutation in a relatively low proportion of cells – 10 to 60 per cent – would have such a big effect. “We were quite amazed,” says David Liu at Harvard University.
    Hutchinson-Gilford progeria syndrome is a rare condition caused when a mutation, which probably took place in the testes or ovaries of a child’s parents, results in a single DNA letter change in one of the two copies of the gene for the lamin A protein. This leads to the production of an abnormal protein called progerin that interferes with cell division and causes many symptoms of premature ageing. The average lifespan of children with progeria is 14 years.
    Advertisement
    Conventional gene therapy, which involves adding genes, cannot help. People with progeria still have one healthy copy of the lamin A gene – the problem is the mutant progerin protein.
    The standard form of CRISPR gene editing, which involves cutting DNA with the Cas9 protein, can be used to disable the mutant gene. The trouble is that it often disables the healthy copy too, as well as causing other unwanted changes.
    Liu’s team has been modifying the Cas9 protein so instead of cutting DNA, it changes one DNA letter to another, a process known as base editing. He and his colleagues have now used a CRISPR base editor to correct the single-letter change that causes almost all cases of progeria, first in skin cells taken from a person with progeria and then in mice with a human version of the lamin A gene.
    Read more: The powerhouses inside cells have been gene-edited for the first time
    A virus carrying the genes for the base editor was injected into the blood of 2-week-old mice – roughly equivalent to 5-year-old children, says Liu – with the progeria mutation. A single injection boosted the median lifespan from 215 to 510 days, and the treated mice were also far more active.
    Because the mice had the human gene, exactly the same approach could be used in human trials. However, Liu’s team has already developed even more efficient base editors.
    In November 2020, the US Food and Drug Administration approved the first-ever drug for treating progeria. In trials, it increased lifespan by an average of 2.5 y tweakbox.mobi/ ears over the maximum follow-up time of 11 years. Liu thinks combining this drug with the CRISPR base editing will work well.
    The findings also boost hopes that many other conditions could be treated through base editing. Half of all known disease-causing mutations involve a single-letter change, most of which can be corrected with existing base editors, says Liu.

    Read more: www.newscientist.com/article/2264168-...
    issue got solved!!
  16. forum rang 7 wiegveld 28 juni 2021 23:00
    Bloomberg:
    See below

    Gene editing stocks are starting the week with a big advance following a major breakthrough for the industry. Early trial data from Intellia Therapeutics (NASDAQ:NTLA), whose shares are up 33% premarket to $117, released interim data from a phase 1 trial of a CRISPR candidate showing the ability to genetically edit cells inside a liver. The data was presented today at the 2021 Peripheral Nerve Society Annual Meeting and in the New England Journal of Medicine.

    What happened? CRISPR technology, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, was previously restricted to editing cells outside the body or in the eye. It also faced challenges like sticking molecular scissors into the body or slicing DNA in a select number of tissues. This time around, researchers injected a CRISPR drug into the blood of people born with transthyretin amyloidosis, a destructive disease that causes fatal nerve and heart disease. The results showed that the editing technology was able to nearly shut off production of the toxic protein generated by their livers by knocking the gene's activity.

    While it's too early to tell whether the CRISPR treatment will ease symptoms of the disease, or if other problems will surface over time, there's still a lot to be excited about. "The allure and the promise of CRISPR is this notion that you can change any gene, anyhow, anywhere in the genome, so long as you can get it there. And that last proviso is the key one," declared Intellia CEO John Leonard. "This is the first time CRISPR has ever been infused into a patient and the first time we've been able to target a gene successfully."

    On the move premarket: Beam Therapeutics (NASDAQ:BEAM) +12%; Editas Medicine (NASDAQ:EDIT) +11%; CRISPR Therapeutics (NASDAQ:CRSP) +8%; ARK Genomic Revolution ETF (BATS:ARKG) +2.5%; Regeneron (NASDAQ:REGN) +1.7%.
  19. forum rang 4 MisterBlues 14 februari 2024 20:15
    Ruim 2 maanden laatste post over dit aandeel. Ten onrechte. Dit aandeel verdient meer aandacht.

    CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

    We expect investors to focus on the sales numbers of CRISPR Therapeutics AG’s CRSP newly approved gene therapy, Casgevy (exa-cel), when the company reports fourth-quarter and full-year 2023 results.
    Factors to Note

    CRISPR Therapeutics’ top line comprises grants and collaboration revenues from its partnership with large-cap biotech Vertex Pharmaceuticals VRTX.

    Vertex leads global development and commercialization of Casgevy under the terms of a 60/40 profit sharing agreement with CRISPR Therapeutics.

    Casgevy is the first marketed product in CRISPR Therapeutics’ portfolio. The commercial launch of Casgevy is currently underway in the United States, United Kingdom, Saudi Arabia and Bahrain.

    Shares of CRISPR Therapeutics have rallied 39.5% in the past year against the industry’s decline 12.8%.

    finance.yahoo.com/news/crispr-crsp-re...

    finance.yahoo.com/news/vertex-vrtx-cr...

    Vertex Pharmaceuticals VRTX and partner CRISPR Therapeutics CRSP announced that the European Commission has granted conditional marketing approval to their one-shot gene therapy Casgevy for treating two debilitating blood disorders, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)...................

    Crispr vandaag 8% up (meer dan er gisteren afging).
  20. forum rang 4 MisterBlues 14 februari 2024 20:26
    European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

    CRISPR Therapeutics AG
    Tue, February 13, 2024 at 8:30 AM GMT+1

    —Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment—

    ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene edited therapy. CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT), for whom hematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen matched related HSC donor is not available.

    CASGEVY is the only genetic therapy approved for SCD and TDT patients in the European Union (EU) and with this approval, there are now more than 8,000 patients potentially eligible for treatment.

    ....................................

    finance.yahoo.com/news/european-commi...
53 Posts
Pagina: «« 1 2 3 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
IMCD 152,900 +8,60 +5,96%
Aperam 27,360 +1,42 +5,47%
HEIJMANS KON 26,200 +1,10 +4,38%
UMG 23,710 +0,46 +1,98%
SBM Offshore 17,810 +0,28 +1,60%
RELX 44,640 +0,66 +1,50%
NSI 19,740 +0,26 +1,33%
Eurocommercial Properties 23,450 +0,30 +1,30%
CTP 14,700 +0,18 +1,24%
Ahold Delhaize 32,390 +0,34 +1,06%
WDP 21,200 +0,22 +1,05%
JUST EAT TAKEAWAY 11,295 +0,12 +1,03%
Vopak 43,080 +0,42 +0,98%
TKH 36,500 +0,32 +0,88%
Wolters Kluwer 161,850 +1,40 +0,87%
AMG Critical Materials N.V. 15,210 +0,13 +0,86%
Wereldhave 14,180 +0,12 +0,85%
Fagron 18,960 +0,16 +0,85%
KPN 3,618 +0,03 +0,81%
BESI 109,500 +0,70 +0,64%
JDE PEET'S 18,850 +0,07 +0,37%
Nedap N.V. 54,800 +0,20 +0,37%
Basic-Fit 22,820 +0,08 +0,35%
ACOMO 17,360 +0,04 +0,23%
BAM 4,160 +0,01 +0,19%
DSM FIRMENICH AG 104,800 +0,05 +0,05%
ING 14,990 +0,01 +0,04%
AZERION 1,296 0,00 0,00%
B&S Group SA 4,500 0,00 0,00%
Kendrion 11,000 0,00 0,00%
Vastned 24,500 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Alfen N.V. 11,700 -1,85 -13,65%
EBUSCO HOLDING 3,390 -0,46 -11,96%
ADYEN NV 1.272,600 -63,20 -4,73%
RANDSTAD NV 42,000 -1,52 -3,49%
INPOST 17,480 -0,47 -2,62%
Pharming 0,738 -0,02 -2,57%
PROSUS 38,440 -1,02 -2,57%
Fugro 16,760 -0,44 -2,56%
Philips Koninklijke 24,870 -0,63 -2,47%
Avantium 2,200 -0,05 -2,44%
Accsys 0,590 -0,01 -2,32%
THEON INTERNAT 8,980 -0,21 -2,29%
CM.COM 6,250 -0,13 -2,04%
FASTNED 21,800 -0,45 -2,02%
Air France-KLM 7,780 -0,16 -2,02%
Brunel 8,780 -0,18 -2,01%
ArcelorMittal 24,140 -0,49 -1,99%
Sif Holding 13,140 -0,24 -1,79%
Galapagos 25,120 -0,42 -1,64%
SIGNIFY NV 21,680 -0,36 -1,63%
Aegon 6,144 -0,09 -1,48%
NX FILTRATION 4,540 -0,07 -1,41%
ALLFUNDS GROUP 5,500 -0,07 -1,26%
PostNL 1,001 -0,01 -1,18%
SHELL PLC 31,250 -0,36 -1,15%
Akzo Nobel 58,820 -0,58 -0,98%
Corbion 22,360 -0,22 -0,97%
EXOR NV 94,650 -0,90 -0,94%
ASR Nederland 44,870 -0,32 -0,71%
ABN AMRO BANK N.V. 15,220 -0,10 -0,69%
TomTom 5,245 -0,04 -0,66%
ASMI 508,800 -2,80 -0,55%
ASML 621,500 -3,20 -0,51%
AEX 874,18 -4,36 -0,50%
Heineken 72,580 -0,36 -0,49%
Flow Traders 21,500 -0,10 -0,46%
RENEWI 7,360 -0,03 -0,41%
OCI 10,700 -0,04 -0,33%
UNILEVER PLC 54,560 -0,14 -0,26%
NN Group 45,130 -0,10 -0,22%
Sligro 11,160 -0,02 -0,18%
AMX 867,36 -1,40 -0,16%
ForFarmers 3,415 0,00 -0,15%
Van Lanschot Kempen NV 41,800 -0,05 -0,12%
ASCX 1.198,78 -1,05 -0,09%
Arcadis 65,100 -0,05 -0,08%
AALBERTS NV 35,120 -0,02 -0,06%
vlag naam koers verschil relatief verschil
AEX 874,18 -4,36 -0,50%
AEX GR 3.422,93 -17,05 -0,50%
Germany40^ 19.238,10 -124,42 -0,64%
FTSE 100 8.072,39 -68,35 -0,84%
EURO50 4.814,83 0,00 0,00%
US30^ 44.011,10 0,00 0,00%
Nasd100^ 21.123,70 0,00 0,00%
US500^ 6.000,22 0,00 0,00%
Japan225^ 39.109,80 0,00 0,00%
VD-NEW 15,36 -0,09 -0,58%
#/^ Index indications calculated real time, zie disclaimer